#AS­CO21: Al­lo­gene sets out to prove that their off-the-shelf ap­proach to CAR-T can beat the per­son­al­ized ap­proach

Al­lo­gene, the next-gen CAR-T com­pa­ny out to prove that their off-the-shelf ap­proach to treat­ing blood can­cers is just as good as the au­tol­o­gous pi­o­neers — or po­ten­tial­ly even bet­ter — is out with a fresh set of da­ta in the lead­up to AS­CO 21 which they be­lieve can go a long way to seal­ing their rep.

The da­ta from their AL­LO-501 AL­PHA tri­al now at the April 19 cut­off did par­tic­u­lar­ly well at the 6-month mark in large B-cell lym­phoma. The bot­tom line:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER